Related Experiment Videos
Beta 1-blockade and acute coronary ischemia. Possible role of platelets
1Department of Clinical Chemistry, Glostrup Hospital, University of Copenhagen, Denmark.
Insights
Metoprolol reduces silent ischemia in coronary artery disease patients, likely by lowering oxygen demand. It also prevented increased platelet aggregation during exercise, suggesting potential benefits beyond heart rate reduction.
Area of Science:
- Cardiology
- Pharmacology
- Platelet Physiology
Background:
- Beta-adrenergic blocking agents are known to benefit acute coronary ischemia.
- The precise mechanisms, including effects on platelet function, remain unclear.
- Metoprolol has shown promise in reducing silent ischemic episodes in stable coronary artery disease.
Purpose of the Study:
- To investigate whether metoprolol's beneficial effects in stable coronary artery disease involve modifications in platelet function.
- To explore the mechanisms behind metoprolol's reduction of silent ischemia, considering both hemodynamic and platelet-related factors.
Main Methods:
- Observational study analyzing metoprolol's impact on silent ischemia episodes.
- Assessment of platelet aggregability at baseline and during circadian cycles.
- Evaluation of platelet function and intracellular cyclic adenosine monophosphate (cAMP) levels during exercise stress testing.
Main Results:
- Metoprolol reduced the number and duration of silent ischemia episodes without altering baseline or circadian platelet aggregability.
- The primary effect appears linked to reduced myocardial oxygen demand due to decreased heart rate and blood pressure.
- Metoprolol prevented exercise-induced increases in platelet aggregability and decreases in intracellular cAMP.
Conclusions:
- Metoprolol's reduction of silent ischemia in stable coronary artery disease is primarily attributed to decreased myocardial oxygen demand.
- Beta-1 adrenergic blockade with metoprolol may offer additional benefits by modulating platelet activation during stress.
- Potential mechanisms for this platelet effect include hemodynamic changes, neurohormonal alterations, or increased platelet-inhibiting substances.
Abstract:
Although the benefit of beta-adrenergic blocking agents in acute coronary ischemia has been well documented, it is unclear whether the responsible mechanisms include the modification of platelet function. In recent studies, metoprolol appeared to reduce the total number and duration of episodes of silent ischemia in patients with stable coronary artery disease throughout the day. This effect was not associated with a change in baseline or circadian variability of the platelet aggregability. Since the treatment caused significant decreases in heart rate and blood pressure, the drug effect is more likely to be based on reduction of myocardial oxygen demand. Metoprolol, however, prevented a platelet aggregability increase and intracellular cAMP decrease during exercise stress testing in patients with stable angina pectoris. We speculate that this effect of beta 1-adrenergic blockade may be due to hemodynamic and neurohormonal changes, or possibly also to an increase in synthesis or release of platelet inhibiting substances.